KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Debt (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Total Debt for 3 consecutive years, with $152.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt rose 7.98% year-over-year to $152.2 million, compared with a TTM value of $152.2 million through Dec 2025, up 7.98%, and an annual FY2025 reading of $152.2 million, up 7.98% over the prior year.
  • Total Debt was $152.2 million for Q4 2025 at Esperion Therapeutics, roughly flat from $151.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $152.2 million in Q4 2025 and bottomed at $141.0 million in Q4 2024.